QUICK SPARK: This New ETF Goes Beyond Eli Lilly, Novo Nordisk and Targets the Peptide Boom

REX Shares has launched the REX Peptide ETF (NASDAQ: PEPT), which aims to provide exposure to the peptide economy beyond major players Eli Lilly and Novo Nordisk. The ETF tracks the VettaFi Peptide Index, consisting of 36 companies across various sectors, with 80% allocated to pure-play peptide firms. J.P. Morgan Global Research projects the global incretin market will reach $200 billion by 2030, highlighting the growing demand for peptide-based treatments. The ETF has an expense ratio of 0.65%.